CRISPR Therapeutics
CRSP
416 hedge funds and large institutions have $2.81B invested in CRISPR Therapeutics in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 133 increasing their positions, 130 reducing their positions, and 73 closing their positions.
2% more repeat investments, than reductions
Existing positions increased: 133 | Existing positions reduced: 130
0.19% more ownership
Funds ownership: 70.16% → 70.34% (+0.19%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
7% less funds holding
Funds holding: 449 → 416 (-33)
13% less capital invested
Capital invested by funds: $3.22B → $2.81B (-$403M)
34% less call options, than puts
Call options by funds: $68.2M | Put options by funds: $103M
40% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 73
Top Buyers
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$37.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$30.4M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$27M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$19.1M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$12.7M |
Top Sellers
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$28.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$20.1M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$14.2M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$12.1M |
| 5 |
CCM
Cutter Capital Management
New York
|
-$10.9M |
CRSP Hedge Fund Activity: Q3 2024 in Review
416 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q3 2024, worth a combined $2.81B — down 13% from $3.22B a quarter earlier.
Sellers outnumbered buyers: 73 funds closed out of CRSP and 44 opened new positions — a net loss of 29 holders — while 130 trimmed existing stakes and 133 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $37.7M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $28.6M sold.
- 416 institutional investors held CRISPR Therapeutics (CRSP) as of Q3 2024, down from 449 in Q2 2024.
- Funds reported $2.81B of CRISPR Therapeutics stock for Q3 2024, down 13% quarter-over-quarter.
- 44 funds opened new CRISPR Therapeutics positions in Q3 2024 and 73 closed out, a net change of -29 holders.
- The largest CRISPR Therapeutics buyer in Q3 2024 was Baker Bros. Advisors, an estimated $37.7M added.
- The largest CRISPR Therapeutics seller in Q3 2024 was Farallon Capital Management, an estimated $28.6M sold.
Based on aggregated 13F filings for Q3 2024.